RhumbLine Advisers’s Denali Therapeutics DNLI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $5.01M | Buy |
194,787
+10,539
| +6% | +$217K | ﹤0.01% | 1464 |
|
|
2026
Q1 | $3.54M | Buy |
184,248
+1,248
| +0.7% | +$24.8K | ﹤0.01% | 1580 |
|
|
2025
Q4 | $3.02M | Sell |
183,000
-18,565
| -9% | -$313K | ﹤0.01% | 1657 |
|
|
2025
Q3 | $2.93M | Sell |
201,565
-10,938
| -5% | -$157K | ﹤0.01% | 1705 |
|
|
2025
Q2 | $2.97M | Buy |
212,503
+22,247
| +12% | +$313K | ﹤0.01% | 1669 |
|
|
2025
Q1 | $2.59M | Sell |
190,256
-134
| -0.1% | -$2.57K | ﹤0.01% | 1687 |
|
|
2024
Q4 | $3.88M | Buy |
190,390
+497
| +0.3% | +$12.7K | ﹤0.01% | 1547 |
|
|
2024
Q3 | $5.53M | Sell |
189,893
-4,966
| -3% | -$123K | 0.01% | 1377 |
|
|
2024
Q2 | $4.52M | Buy |
194,859
+22,900
| +13% | +$440K | ﹤0.01% | 1454 |
|
|
2024
Q1 | $3.53M | Buy |
171,959
+5,196
| +3% | +$97.7K | ﹤0.01% | 1600 |
|
|
2023
Q4 | $3.58M | Sell |
166,763
-2,361
| -1% | -$46.8K | ﹤0.01% | 1606 |
|
|
2023
Q3 | $3.49M | Buy |
169,124
+7,142
| +4% | +$181K | ﹤0.01% | 1550 |
|
|
2023
Q2 | $4.78M | Buy |
161,982
+15,840
| +11% | +$445K | 0.01% | 1402 |
|
|
2023
Q1 | $3.37M | Buy |
146,142
+3,210
| +2% | +$88.3K | ﹤0.01% | 1546 |
|
|
2022
Q4 | $3.98M | Buy |
142,932
+14,999
| +12% | +$446K | 0.01% | 1411 |
|
|
2022
Q3 | $3.93M | Buy |
127,933
+10,458
| +9% | +$340K | 0.01% | 1371 |
|
|
2022
Q2 | $3.46M | Buy |
117,475
+20,330
| +21% | +$533K | 0.01% | 1465 |
|
|
2022
Q1 | $3.13M | Buy |
97,145
+496
| +0.5% | +$17.1K | ﹤0.01% | 1582 |
|
|
2021
Q4 | $4.31M | Sell |
96,649
-756
| -0.8% | -$35.8K | 0.01% | 1438 |
|
|
2021
Q3 | $4.91M | Buy |
97,405
+2,550
| +3% | +$144K | 0.01% | 1372 |
|
|
2021
Q2 | $7.44M | Buy |
94,855
+23,280
| +33% | +$1.44M | 0.01% | 1189 |
|
|
2021
Q1 | $4.09M | Sell |
71,575
-8,048
| -10% | -$539K | 0.01% | 1523 |
|
|
2020
Q4 | $6.67M | Buy |
79,623
+528
| +0.7% | +$31.9K | 0.01% | 1187 |
|
|
2020
Q3 | $2.83M | Sell |
79,095
-11,820
| -13% | -$356K | ﹤0.01% | 1496 |
|
|
2020
Q2 | $2.2M | Buy |
90,915
+24,985
| +38% | +$587K | ﹤0.01% | 1674 |
|
|
2020
Q1 | $1.15M | Buy |
65,930
+2,418
| +4% | +$50.4K | ﹤0.01% | 1815 |
|
|
2019
Q4 | $1.11M | Buy |
63,512
+782
| +1% | +$13K | ﹤0.01% | 2030 |
|
|
2019
Q3 | $961K | Sell |
62,730
-657
| -1% | -$12.6K | ﹤0.01% | 2050 |
|
|
2019
Q2 | $1.32M | Buy |
63,387
+3,204
| +5% | +$71.8K | ﹤0.01% | 1942 |
|
|
2019
Q1 | $1.4M | Sell |
60,183
-666
| -1% | -$13.9K | ﹤0.01% | 1890 |
|
|
2018
Q4 | $1.26M | Buy |
60,849
+22,712
| +60% | +$412K | ﹤0.01% | 1900 |
|
|
2018
Q3 | $829K | Buy |
38,137
+21,926
| +135% | +$363K | ﹤0.01% | 2083 |
|
|
2018
Q2 | $247K | Buy |
16,211
+2,306
| +17% | +$43.5K | ﹤0.01% | 2627 |
|
|
2018
Q1 | $274K | Buy |
+13,905
| New | +$286K | ﹤0.01% | 2479 |
|
Other funds holding DNLI
RhumbLine Advisers's DNLI Position: Q2 2026 in Review
RhumbLine Advisers increased its Denali Therapeutics (DNLI) stake by 5.7% in Q2 2026, buying an estimated $217K and bringing the position to 194,787 shares worth $5.01M. The position accounts for ﹤0.01% of the portfolio, ranked #1464.
RhumbLine Advisers first reported a position in DNLI in Q1 2018 and has held it in 34 quarters since. The position peaked at $7.44M in Q2 2021. 292 funds tracked by Wall St. Rank hold DNLI as of Q2 2026.
- RhumbLine Advisers held 194,787 shares of Denali Therapeutics worth $5.01M as of Q2 2026.
- RhumbLine Advisers bought 10,539 Denali Therapeutics shares in Q2 2026, an estimated $217K.
- Denali Therapeutics made up ﹤0.01% of RhumbLine Advisers's portfolio in Q2 2026, its #1464 holding.
- RhumbLine Advisers first reported a position in Denali Therapeutics in Q1 2018 and has held it in 34 quarters since.
- RhumbLine Advisers's Denali Therapeutics position peaked at $7.44M in Q2 2021.
- 292 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2026.
Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.